Next Article in Journal
Insights on Oligometastatic Non-Small-Cell Lung Cancer
Previous Article in Journal
Correction: Al Bitar et al. Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models. Cancers 2022, 14, 1363
Previous Article in Special Issue
Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: ter Woerds et al. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700

by
Desi K. M. ter Woerds
1,
Roel L. J. Verhoeven
1,*,
Ad F. T. M. Verhagen
2,
Erik H. J. G. Aarntzen
3,4,5 and
Erik H. F. M. van der Heijden
1
1
Department of Pulmonary Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
2
Department of Thoracic Surgery, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
3
Department of Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
4
Department Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands
5
Department of Nuclear Medicine, Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(15), 2450; https://doi.org/10.3390/cancers17152450
Submission received: 14 July 2025 / Accepted: 15 July 2025 / Published: 24 July 2025
(This article belongs to the Special Issue Advances in Lung Ultrasound in Cancer Patients)
Error in Table
In the original publication [1], there was a mistake in Appendix B, Table A2, as published. The calculations concerning patients with a negative EBUS and a pN0 stage after surgery were incorrect. The previous version incorrectly assumed that all 88 patients underwent surgery within six weeks after navigation bronchoscopy. However, this was not the case. An additional specificity has now been calculated, and the negative predictive values (NPV) for this subgroup have been adjusted accordingly. The corrected Table A2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. ter Woerds, D.K.M.; Verhoeven, R.L.J.; Verhagen, A.F.T.M.; Aarntzen, E.H.J.G.; van der Heijden, E.H.F.M. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700. [Google Scholar] [CrossRef] [PubMed]
Table A2. The sensitivity, specificity, PPV, and NPV of EBUS in the cohort of lung cancer patients with cytologically confirmed N-status by EBUS or pN-status confirmed by surgery. a One false-positive lymph node (atypical cells in pathology, MDT decision cN1). b In two patients, only micrometastases were found in station 12, which is inaccessible by EBUS. Additional calculations were performed by excluding patients with nodal involvement in EBUS inaccessible regions. c In six patients, surgery was performed after more than 6 weeks due to comorbidities, neo-adjuvant treatment, or treatments of synchronous cancers. In this subgroup, pulmonary surgery was performed 47 to 136 days after the NB + EBUS, and they were, therefore, left out of this secondary analysis. Abbreviations: EBUS, Endobronchial Ultrasound; NB, Navigation Bronchoscopy; NNT, Number Needed to Treat; NPV, Negative Predictive Value; PPV, Positive Predictive value.
Table A2. The sensitivity, specificity, PPV, and NPV of EBUS in the cohort of lung cancer patients with cytologically confirmed N-status by EBUS or pN-status confirmed by surgery. a One false-positive lymph node (atypical cells in pathology, MDT decision cN1). b In two patients, only micrometastases were found in station 12, which is inaccessible by EBUS. Additional calculations were performed by excluding patients with nodal involvement in EBUS inaccessible regions. c In six patients, surgery was performed after more than 6 weeks due to comorbidities, neo-adjuvant treatment, or treatments of synchronous cancers. In this subgroup, pulmonary surgery was performed 47 to 136 days after the NB + EBUS, and they were, therefore, left out of this secondary analysis. Abbreviations: EBUS, Endobronchial Ultrasound; NB, Navigation Bronchoscopy; NNT, Number Needed to Treat; NPV, Negative Predictive Value; PPV, Positive Predictive value.
Accuracy of EBUS in Surgically Treated cN0 Lung Cancer Patients
(See Main Manuscript for cTNM and pTNM Details, Median Tumor Size 17 mm)
Lung cancer patient subgroup: NB + EBUS with surgical confirmation (n = 118)Pathology N-status
pN+pN−Total
EBUS N+121 a13
EBUS N−, all (accessible b)17 (15)88105
EBUS N−, surgery < 6w after NB (accessible b) c12 (10)61
Total2989118
Sensitivity (all)12/(12 + 17)41.4%
Sensitivity (EBUS accessible)12/(12 + 15)44.4%
Sensitivity (surgery < 6w after NB)12/(12 + 12)50.0%
Sensitivity (surgery < 6w after NB + EBUS accessible)12/(12 + 10)54.5%
Specificity (all)88/(1 + 88)98.9%
Specificity (surgery < 6w after NB)61/(1 + 61)98.4%
PPV12/(12 + 1)92.3%
NPV (all)88/(17 + 88)83.8%
NPV (EBUS accessible)88/(15 + 88)85.4%
NPV (surgery < 6w after NB)61/(12 + 61)83.6%
NPV (surgery < 6w after NB + EBUS accessible)61/(10 + 61)85.9%
Overall accuracy(12 + 88)/11884.7%
NNT overall10
NNT iN+ subgroup4
NNT iN− subgroup
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

ter Woerds, D.K.M.; Verhoeven, R.L.J.; Verhagen, A.F.T.M.; Aarntzen, E.H.J.G.; van der Heijden, E.H.F.M. Correction: ter Woerds et al. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700. Cancers 2025, 17, 2450. https://doi.org/10.3390/cancers17152450

AMA Style

ter Woerds DKM, Verhoeven RLJ, Verhagen AFTM, Aarntzen EHJG, van der Heijden EHFM. Correction: ter Woerds et al. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700. Cancers. 2025; 17(15):2450. https://doi.org/10.3390/cancers17152450

Chicago/Turabian Style

ter Woerds, Desi K. M., Roel L. J. Verhoeven, Ad F. T. M. Verhagen, Erik H. J. G. Aarntzen, and Erik H. F. M. van der Heijden. 2025. "Correction: ter Woerds et al. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700" Cancers 17, no. 15: 2450. https://doi.org/10.3390/cancers17152450

APA Style

ter Woerds, D. K. M., Verhoeven, R. L. J., Verhagen, A. F. T. M., Aarntzen, E. H. J. G., & van der Heijden, E. H. F. M. (2025). Correction: ter Woerds et al. Endobronchial Ultrasound Staging During Navigation Bronchoscopy for Peripheral Pulmonary Nodules in the Real World: Which Patients Will Benefit? Cancers 2025, 17, 1700. Cancers, 17(15), 2450. https://doi.org/10.3390/cancers17152450

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop